参考资料: [1] European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy. Retrieved October 16, 2023, from https://www.merck.com/news/european-commis...
原文链接: https://www.biospace.com/article/releases/leap-therapeutics-announces-completion-of-enrollment-in-part-a-of-the-defiance-study-of-dkn-01-for-the-treatment-of-colorectal-cancer-patients/ ⑤ Kineta实体瘤药物KVA12123 1/2期临床首例患者接受治疗 作者:Biospace 解读:Alex Zhang 来源:Biospace ...
Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab) has been cleared by the European Commission to treat two new indications in gynecologic cancers. The first approval is for Keytruda, in combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced...
原文链接: https://www.biospace.com/article/releases/leap-therapeutics-announces-completion-of-enrollment-in-part-a-of-the-defiance-study-of-dkn-01-for-the-treatment-of-colorectal-cancer-patients/ ⑤Kineta实体瘤药物KVA12123 1/2期临床首例患者接受治疗 作者:Biospace 解读:Alex Zhang 来源:Biospace 发...
FDA approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) 我们特别建了“患者交流群”,欢迎肿瘤患者/家属扫描下方二维码,加入交流群,大家一...
[2] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-non-small-cell-lung-cancer 关注MORE Health,关注最新医疗资讯。如果您或者您的亲人在人生的道路上无意中碰上了肿瘤癌症、疑难...
三阴性乳腺癌、原发性纵隔大B细胞淋巴瘤等。参考来源：Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer. NEJM, DOI: 10.1056/NEJMoa2302983[3] FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a ...
今日,默沙东公司宣布,其重磅PD-1抑制剂Keytruda在3期临床试验KEYNOTE-811中达到主要终点,与抗HER2抗体曲妥珠单抗和化疗联用,作为一线疗法治疗HER2阳性,不可切除的局部晚期或转移性胃癌或胃食管结合部(GEJ)腺癌患者时,显著延长患者的总生存期(OS)。此前,美国FDA已经基于这一试验的客观缓解率(ORR)和缓解持续时间数据...
Learn about how KEYTRUDA® (pembrolizumab) may be used with axitinib for patients with advanced kidney cancer or as adjuvant treatment for certain patients with kidney cancer (renal cell carcinoma).